Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050949 | 0.91 | OPRM1 (0.47) | OPRM1HPGDCTSLCTSBCTSK | |
| SCHEMBL13050868 | 0.91 | OPRM1 (0.47) | OPRM1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL13050888 | 0.88 | OPRM1 (0.47) | OPRM1P2RX7SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13050963 | 0.88 | OPRM1 (0.47) | OPRM1HPGDGAASMN1; SMN2NPC1 | |
| SCHEMBL13050896 | 0.88 | OPRM1 (0.47) | OPRM1P2RX7SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13050973 | 0.88 | OPRM1 (0.47) | OPRM1HPGDGAASMN1; SMN2NPC1 | |
| SCHEMBL13050921 | 0.85 | SLC6A4 (0.50) | NPC1RAB9AMEN1CYP1A2CYP3A4 | |
| SCHEMBL13050992 | 0.85 | SLC6A2 (0.42) | OPRM1HPGDNPC1RAB9AKDM1A | |
| SCHEMBL13050986 | 0.85 | SLC6A2 (0.42) | OPRM1HPGDNPC1RAB9AKDM1A | |
| SCHEMBL13050916 | 0.85 | SLC6A4 (0.50) | NPC1RAB9AMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009036275-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS | LINK MEDICINE CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | OPRM1 771/4885HPGD 1640/4885GAA 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.